Liquid Encapsulation Utilizing An Emulsion Or Dispersion To Form A Solid-walled Microcapsule (includes Liposome) Patents (Class 264/4.1)
  • Patent number: 10413511
    Abstract: The present invention relates to the preparation of liposomes with enhanced loading capacity for pharmaceutically and/or diagnostically active agents and/or cosmetic agents which are substantially solubilized by the liposomal membranes, to liposome dispersions with enhanced stability with respect to release of the active agent and/or cosmetic agent from the liposomes obtainable by the process, and to pharmaceutical or cosmetic compositions comprising said stabilized liposome dispersions. The preparation may involve dehydration and rehydration steps of liposome dispersions which may be carried out by spray drying.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: September 17, 2019
    Assignee: SynCore Biotechnology Co., Ltd.
    Inventors: Heinrich Haas, Ursula Fattler
  • Patent number: 10400012
    Abstract: Peptides having a human minute binding protein-2 (HDM-2) targeting sequence are capable of targeting the human minute binding protein-2. Peptides having an HDM-2 targeting sequence may be used to treat cancer.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 3, 2019
    Assignee: SLH Innovations LLC
    Inventor: Matthew R. Pincus
  • Patent number: 10403834
    Abstract: A flexible display device including a hard coating layer, the hard coating layer containing first hard coating oligomers, second hard coating oligomers having greater molecular weights than the first hard coating oligomers, a cross-linker, and a photoinitiator. The first hard coating oligomers may maintain the hardness of the hard coating layer and the second hard coating oligomers may improve the flexibility of the hard coating layer, such that damage to the hard coating layer may be prevented or reduced even when the flexible display device is bent.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: September 3, 2019
    Assignee: Samsung Display Co., Ltd.
    Inventors: Youngsang Park, Chulho Jeong, Ahyoung Kim
  • Patent number: 10383900
    Abstract: This disclosure provides, inter alia, systems and methods for storage and delivery of ammonia oxidizing bacteria, and preparations comprising ammonia oxidizing bacteria. The ammonia oxidizing bacteria may be provided in a container or a kit, with one or more other components that may enhance delivery. The systems and methods herein may be used, for instance, to treat diseases associated with low nitrite levels, skin diseases, and diseases caused by pathogenic bacteria.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: August 20, 2019
    Assignee: AOBIOME LLC
    Inventors: James Heywood, Spiros Jamas, David R. Whitlock, Larry Weiss
  • Patent number: 10364280
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERTX4AX6WEIX10X11LPNLX16X17X18QX20GAFIX25X26LHD. The present disclosure also relates to the use of such a PD-L1 binding polypeptide a prognostic and/or diagnostic agent as well as a therapeutic agent.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: July 30, 2019
    Assignee: AFFIBODY AB
    Inventor: Elisabet Wahlberg
  • Patent number: 10342830
    Abstract: This document provides methods and materials for treating lung conditions induced by inhalable insulin therapy. For example, compositions including a dried amnion tissue preparation and/or a dried stem cell preparation as well as methods for using such compositions to treat inhalable insulin induced lung conditions are provided.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: July 9, 2019
    Inventor: Gary M. Petrucci
  • Patent number: 10322191
    Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: June 18, 2019
    Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
  • Patent number: 10314946
    Abstract: Hydrogels and composite material containing hydrogels and liposomes dispersed therein, which exhibit a reduced friction coefficient compared to neat hydrogels or composites containing hydrogels, processes for preparing the same, and methods for using the same are disclosed.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: June 11, 2019
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Jacob Klein, Ronit Goldberg, Noa Iuster, Raya Sorkin
  • Patent number: 10307490
    Abstract: Described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a targeting agent. The composition can include a therapeutic agent. The therapeutic agent can be an antisense oligonucleotide (ASO). Exemplary ASOs are targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1; or targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Also described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a therapeutic agent that is an ASO such as an ASO targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1 or an ASO targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Pharmaceutical formulations, methods of making the lipid nanoparticles, and methods of using the lipid nanoparticles, for example for treating cancers, are also disclosed.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: June 4, 2019
    Assignee: The Ohio State University
    Inventors: Robert J. Lee, Young Bok Lee, Deog Joong Kim, Chang Ho Ahn
  • Patent number: 10308682
    Abstract: Disclosed herein are fibrillar molecular aggregates, which are morphologically and phenotypically similar to oligomers of aberrant proteins. The molecular aggregates, formed by self-assembly of small hydrophobic molecules, prevent the growth of microtubules. This unprecedented mechanism of “self-assembly to interfere with self-organization” allows inhibition of the growth of cancer cells.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: June 4, 2019
    Assignee: Brandeis University
    Inventors: Bing Xu, Yi Kuang
  • Patent number: 10301506
    Abstract: A process for preparing polymer. An embodiment of a method includes generating a resin solution including a first reaction solvent and a polymer resin dissolved therein; deploying the resin solution into a precipitation solvent contained in a chamber of a reaction vessel, wherein deploying the resin solution includes generating droplets of the resin solution; disturbing a resulting mixture of the resin solution and the precipitation solvent, wherein the mixture produces a precipitate; and generating a polymer powder from the mixture, including isolating the precipitate from a remaining portion of the mixture, and drying the isolated precipitate.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: May 28, 2019
    Assignee: Cymer-Dayton, LLC
    Inventors: Limor Ben-Asher, David Edward Noga, Zhongliang Zhu, Anderson Bouton
  • Patent number: 10285405
    Abstract: The present disclosure provides a particulate matter comprising particles carrying an essentially dry combination of components comprising at least one natural oil and at least one surfactant, the components being selected such that upon contact with water, oil in water emulsion is formed. In particular, the emulsion formed is a stable emulsion, with stability of at least several hours, as observed by the lack of phase separation during that time.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: May 14, 2019
    Assignee: Nobactra Israel Ltd.
    Inventor: Giora Kritzman
  • Patent number: 10273267
    Abstract: ?-Hairpin peptidomimetics of the general formula cyclo(-Xaa1-Xaa2-Thr3-Xaa4-Ser5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-) and pharmaceutically acceptable salts thereof, with Xaa1, Xaa2, Xaa4, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12 and Xaa13 being amino acid residues of certain types which are defined in the description and the claims, have elastase inhibitory properties, especially against human neutrophil elastase, and can be used for preventing infections or diseases related to such infections in healthy individuals or for slowing infections in infected patients. The compounds of the invention can further be used where cancer, or immunological diseases, or pulmonary diseases, or cardiovascular diseases, or neurodegenerative diseases, or inflammation, or diseases related to inflammation, are mediated or resulting from elastase activity. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: April 30, 2019
    Assignee: POLYPHOR AG
    Inventors: Frank Otto Gombert, Daniel Obrecht, Odile Sellier-Kessler, Alexander Lederer, Christian Ludin, Manuella Schmitt-Billet, Steffen Weinbrenner
  • Patent number: 10258570
    Abstract: The invention relates to liposomes for pulmonary application, advantageously comprising at least one first and at least one second phospholipid, cholesterol, and at least one active substance and/or colorant, wherein the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably selected from the group DMPC, DPPC, DPPE. It is thereby advantageous if the first and the second phospholipid are present at a molar ratio of 0.5:1 to 10:1, preferably at a ratio of 6:1 to 2:1, in particular preferably at a ratio of 3:1. It is further advantageous if the molar ratio between phospholipids and cholesterol is between 10:1 and 1:1, preferably between 6:1 and 3:1, in particular preferably 4:1. The second phospholipid is further preferably DMPC or DPPE, in particular preferably DPPE. The size of the liposomes is advantageously between 0.05 ?m and 5 ?m, preferably between 0.2 ?m and 2.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: April 16, 2019
    Assignee: Lung Biotechnology Inc.
    Inventors: Tobias Gessler, Thomas Schmehl, Monika Rieger
  • Patent number: 10241045
    Abstract: Spectrally encoded microbeads and methods and devices for making and using spectrally encoded microbeads are provided. The disclosed methods and devices facilitate the preparation and use of microbeads containing multiple lanthanide nanoparticles, which microbeads have uniquely identifiable spectral codes. The disclosed microbeads, and the methods and devices for making and using same, find use in multiplexing and high-throughput biomarker analysis.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: March 26, 2019
    Assignee: The Regents of the University of California
    Inventors: Brian Cullen Baxter, Joseph L. Derisi, Polly M. Fordyce, Rachel E. Gerver, Rafael Gòmez-Sjöberg, Brett A. Helms, Kurt S. Thorn, Ronald N. Zuckermann
  • Patent number: 10232013
    Abstract: The preset invention relates to a new approach for treating a cancer, particularly a malignant tumor, a multidrug-resistant (MDR) cancer, a recurrent cancer or a metastatic cancer, using a specific cationic antimicrobial peptide (CAP), tilapia piscidin 4 (TP4), which is derived from Nile Tilapia (Oreochromis niloticus). Also provided is a method for treating a breast cancer, particularly triple negative breast cancer (TNBC) with TP4.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: March 19, 2019
    Assignee: Academia Sinica
    Inventors: Jyh-Yih Chen, Chen-Hung Ting
  • Patent number: 10220095
    Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: March 5, 2019
    Inventors: Pei Kan, Yun-Long Tseng, Han-Chun Ou, Chun-yen Lai
  • Patent number: 10214704
    Abstract: A lubricating oil comprises a base oil; and an anti-degradation additive comprising microcapsules, nanocapsules, or a combination comprising at least one of the foregoing; the microcapsules and the nanocapsules each independently having a core of a neutralizing material and a polymeric encapsulant configured to release the neutralizing material in an acidic environment by breaking crosslinks or hydrogen bonds in the polymeric encapsulant. The released neutralizing material can prevent the formation of viscous, high molecular weight molecules thus enhancing the lifetime of the lubricating oil and improving its reliability.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 26, 2019
    Inventors: Darryl Ventura, Rostyslav Dolog, Oleg A. Mazyar, Valery Khabashesku, Qusai Darugar
  • Patent number: 10206272
    Abstract: The present invention relates to a method for manufacturing a tracer-encapsulated solid pellet for magnetic-confinement fusion, the method comprising a liquid droplet formation step of discharging an organic liquid containing an organic solvent into a stabilizing liquid to thereby form liquid droplets 12, and an organic solvent removal step of removing the organic solvent from the liquid droplets 12A. The organic liquid to be used is a liquid having a first organic polymer containing tracer atoms and a second organic polymer being an organic polymer different from the first organic polymer dissolved in the organic solvent, wherein the first organic polymer and the second organic polymer can be mutually phase-separated.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: February 12, 2019
    Inventors: Nakahiro Satoh, Ryo Yoshimura, Masaru Takagi, Toshiyuki Kawashima, Hirofumi Kan
  • Patent number: 10201508
    Abstract: A method of producing positively charged liposome vesicles for use as carriers of lipophilic molecules. A mixture of hydrogenated phospholipids, a cationic excipient and a lipophilic molecule are dissolved in a solvent to form a composition. The composition is dried to remove the solvent. The dried composition is hydrated to form liposome vesicles and optionally the liposome vesicles are homogenized to form smaller vesicles. The vesicles are useful for delivery lipophilic molecules, such as, but limited to, lutein and zeaxanthin, to ocular tissues using iontophoresis.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: February 12, 2019
    Inventor: Diogo de Sousa Martins
  • Patent number: 10195577
    Abstract: A process for producing microcapsules containing a shell and a core of a liquid water-insoluble material is disclosed. The microcapsules are prepared using a bifunctional isocyanate, an anionically modified diisocyanate, a bifunctional amine, and a protective colloid. The protective colloid is a polyvinyl alcohol copolymer having hydrolysis degrees from 85 to 99.9%.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: February 5, 2019
    Assignee: BASF SE
    Inventors: Ewelina Burakowska-Meise, Wolfgang Denuell, Ulrich Issberner
  • Patent number: 10190208
    Abstract: Methods for obtaining a profile for a batch, or lot, of a precursor material and using the profile while processing the precursor material to form a polymer are disclosed. In such a method, a process profile that corresponds to the characteristics of a particular precursor material (e.g., the batch, etc.) may be generated. That process profile may then be used to cause a material processing system to process the precursor material in a manner that accounts for differences between that precursor material and a “standard” precursor material, while providing a polymer and, optionally, a film of “standard” quality. Apparatuses and systems that are configured to obtain profile data for a batch of precursor material, generate or modify a process profile based on the profile data and use the process profile to form a polymer are also disclosed.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: January 29, 2019
    Assignee: HZO, INC.
    Inventor: James D. Dempster
  • Patent number: 10189875
    Abstract: Provided are a peptide consisting of the amino acid sequence of SEQ ID NO:1 or a pharmaceutically acceptable salt thereof, and the use thereof. Cancer can be effectively prevented or treated by application of the peptide.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: January 29, 2019
    Inventors: Hae Jin Kim, Duk Soon Hwang, Eun Joung Moon
  • Patent number: 10188699
    Abstract: Administration of compositions comprising cell-permeable cancer-specific proliferating cell nuclear antigen derived peptides and their variants reduces the proliferation of cancer cells and also augments cytotoxic effects of chemotherapeutics. The compositions are effective in cells harboring mutations in DNA repair proteins.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: January 29, 2019
    Inventors: Robert J. Hickey, Linda H. Malkas
  • Patent number: 10179106
    Abstract: The present invention provides liposomes comprising a lipid bilayer and a polymer-conjugated lipid, wherein said polymer-conjugated lipid is incorporated into said lipid bilayer. The present invention also provides methods of producing the liposomes as well as a method of delivering a nucleic acid to a subject comprising the step of administering said nucleic acid encapsulated in a mixed liposome, a method for performing diagnostic imaging in a subject, comprising the step of administering a diagnostic agent encapsulated in a mixed liposome, and methods for treating, inhibiting, or suppressing a pathological condition in a subject comprising administering to said subject a mixed liposome.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: January 15, 2019
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventor: Saul Yedgar
  • Patent number: 10173192
    Abstract: A quad-centric nozzle and system for hydrocapsule encapsulation is disclosed. In at least one embodiment, a quad-centric nozzle is disclosed for encapsulating discrete droplets of liquid by generating a continuous coating or layer of a polymerizable liquid which is substantially immiscible with the core liquid. In at least one embodiment, the quad-centric nozzle includes: a material feed port assembly, a polymer feed port assembly, a first water feed port assembly, a second water feed port assembly and an encapsulated material exit port assembly. In at least one embodiment, the quad-centric nozzle is configured for use in a system for hydrocapsule encapsulation having a pressure control system, a water control system and sparging column, and an ultraviolet exposure chamber system.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: January 8, 2019
    Inventors: Michael Pitsokos, Ara Manukian, William Toreki
  • Patent number: 10167316
    Abstract: Provided are a peptide consisting of the amino acid sequence of SEQ ID NO:1 or a pharmaceutically acceptable salt thereof, and the use thereof. Cancer can be effectively prevented or treated by application of the peptide.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: January 1, 2019
    Inventors: Hae JIn Kim, Duk Soon Hwang, Eun Joung Moon
  • Patent number: 10166220
    Abstract: The present invention provides a pharmaceutical composition comprising taste-masked immediate release microcapsules which comprise fexofenadine and a water-insoluble polymer coating. These microcapsules and the pharmaceutical compositions comprising them have suitable drug content and desirable pharmaceutical properties, including a quick dissolution rate of fexofenadine combined with a taste masking effect.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: January 1, 2019
    Inventors: Luigi Mapelli, Flavio Fabiani, Luigi Boltri, Paolo Gatti, Mauro Serratoni, Roberto Cassanmagnago
  • Patent number: 10154968
    Abstract: Stable nanoparticle compositions comprising buprenorphine and at least one biodegradable polymer. The disclosure also provides methods of controlling pain in an animal and methods of treating addiction in a human utilizing the stable nanoparticle compositions, as well as pharmaceutical formulations comprising the stable nanoparticle compositions. The stable nanoparticle compositions are capable of releasing buprenorphine over several days, weeks, or months following administration. The stable nanoparticle compositions of buprenorphine utilize biodegradable polymers capable of degrading into non-toxic components in the body of an animal and may be excreted in the urine of the animal following their metabolism in the body. The stable nanoparticle compositions can advantageously provide sustained release of buprenorphine in the body after a single administration without the need for surgical removal of implanted matrices subsequent to depletion of the drug.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: December 18, 2018
    Inventors: William R. Ravis, Yuh-Jing Lin
  • Patent number: 10137089
    Abstract: Embodiments may also include a system for reducing a solvent concentration in a plurality of microparticles. The system may include a solvent extraction tank. In the solvent extraction tank, a mixture including the plurality of microparticles and the solvent may be contacted with water to form an aqueous suspension. A first portion of the solvent may dissolve into the water of the aqueous suspension to reduce the solvent concentration in the plurality of microparticles. The system may also include a concentration unit in fluid communication with the solvent extraction tank. The concentration unit may further reduce the solvent concentration in the plurality of microparticles. A microparticle concentrate may be formed. The system may further include a washing unit. In the washing unit, the microparticle concentrate may be contacted with a washing solution and may form an amalgam of washed particles.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: November 27, 2018
    Assignee: Rezolute, Inc
    Inventor: Greg Bryden Sebring
  • Patent number: 10137079
    Abstract: Described is a transdermal ethosome composition for the treatment of pain. The transdermal ethosome composition comprises: an alcohol; a phospholipid; water; and a magnesium salt, a TRPV1 receptor agonist, or both a magnesium salt and a TRPV1 receptor agonist. The present compositions can be used to treat pain that is muscular, nociceptive or neuropathic in origin.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: November 27, 2018
    Assignee: CURA HEALTH INC.
    Inventor: Moheb Maalawy
  • Patent number: 10111853
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one carboxylate or carbamate ligand.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: October 30, 2018
    Inventors: Mark T. Bilodeau, Craig A. Dunbar, Timothy E. Barder, Edward R. Lee, Rossitza G. Alargova, Danielle N. Rockwood, Rajesh Shinde, Patrick Lim Soo, Benoît Moreau
  • Patent number: 10098841
    Abstract: Provided is a bilayer membrane vesicle capable of undergoing a phase transition. The bilayer membrane vesicle includes: (a) a fatty acid salt having 6 to 20 carbon atoms; (b) an alcohol or an amine compound having an aliphatic chain of 6 to 20 carbon atoms; and (c) an artificial synthetic lipid or a phospholipid capable of forming a bilayer membrane. Preferably, this bilayer membrane vesicle further contains (d) a tertiary amine as a component of the membrane. Also provided is a method of inducing a phase transition of a bilayer membrane vesicle, the method including the step of adding a dehydrating condensing agent or a dehydrating condensing agent precursor having the property of accumulating at an interface to the bilayer membrane vesicle. By causing the lipids that form a molecular aggregate to chemically change, it is possible to change the physical property and the morphology of the molecular aggregate and control the timing of phase transitions such as membrane fusion.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: October 16, 2018
    Assignee: Japan Science and Technology Agency
    Inventor: Munetaka Kunishima
  • Patent number: 10092486
    Abstract: Poiyurea or polyurethane capsule compositions. A subset of these compositions contain a plurality of capsules and a capsule formation aid, in which each of the capsules contains a poiyurea or polyurethane wall and an oil core; the poiyurea or polyurethane wall is formed of a reaction product of a polyisocyanate and a cross-linking agent in the presence of the capsule formation aid; and the oil core contains an active material. The polyisocyante, cross-linking agent, and capsule formation aids are described herein. Also disclosed are methods of preparing poiyurea and polyurethane capsule compositions, as well as consumer products containing one of these compositions.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: October 9, 2018
    Inventors: Yabin Lei, Li Xu, Lewis Michael Popplewell
  • Patent number: 10092515
    Abstract: The present invention provides an intravenous liposomal formulation of a low dose polymyxin B or a pharmaceutical composition thereof. The present invention also provides methods utilizing the intravenous liposomal formulation or its pharmaceutical composition for increasing the therapeutic efficacy during treatment of a bacterial infection in a subject, for decreasing exposure of renal tissue to the polymyxin B during a course of polymyxin B treatment and for lowering exposure to polymyxin B in renal tissues in a subject receiving polymyxin B treatment.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: October 9, 2018
    Assignee: University of Houston System
    Inventors: Vincent Tam, Diana Chow, Jie Gohlke
  • Patent number: 10087230
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: October 2, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Maria R. Parkhurst, Richard A. Morgan, Steven A. Rosenberg, Shannon Faith Rosati
  • Patent number: 10064976
    Abstract: A system is provided, including a plurality of donor cells and a first alginate structure that encapsulates the plurality of donor cells. The first alginate structure has a guluronic acid concentration of between 64% and 74%. The system additionally includes a second alginate structure that surrounds the first alginate structure, the second alginate structure having a mannuronic acid concentration of between 52% and 60%. A selectively-permeable membrane is coupled at least in part to the second alginate structure. Other embodiments are also described.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: September 4, 2018
    Assignee: Beta-O2 Technologies Ltd.
    Inventors: Uriel Barkai, Avi Rotem, Yehezkel Bremer, Tova Neufeld
  • Patent number: 10059740
    Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 28, 2018
    Inventors: Lori Hazlehurst, Mark McLaughlin, Priyesh Jain, William S. Dalton
  • Patent number: 10052303
    Abstract: The present invention provides stable, fast-acting liposomal and micelle formulations of cannabinoids that are suitable for pharmaceutical and nutraceutical applications.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: August 21, 2018
    Inventor: Robert Winnicki
  • Patent number: 10041129
    Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: August 7, 2018
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: James J. Mulé, Domenico Coppola, Timothy J. Yeatman, Andrey Loboda, Michael V. Nebozhyn
  • Patent number: 10039715
    Abstract: The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: August 7, 2018
    Inventors: Vincenzo Cerundolo, Simon Eastman
  • Patent number: 10035338
    Abstract: A method of adhering first and second elongate webs includes depositing a first component of a two-component adhesive on a first face of the first elongate web and depositing a second component of the two-component adhesive on a first face of the second elongate web. The first face of the first elongate web and the first face of second elongate web are brought into contact, and the two components are mixed ultrasonically. In an alternate method, a two-component adhesive on at least a first face of the first elongate web, with at least one of the two components micro-encapsulated so that the two components of the two-component adhesive do not react. The first face of the first elongate web and the first face of the second elongate web are brought into contact. Ultrasound and/or heat is applied to free the microencapsulated components of the two-component adhesive, so that the components of the two component adhesive can react.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: July 31, 2018
    Assignee: MARK ANDY, INC.
    Inventor: John Bailey Howard
  • Patent number: 10028912
    Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: July 24, 2018
    Inventors: Donna Cabral-Lilly, Lawrence Mayer, Paul Tardi, David Watkins, Yi Zeng
  • Patent number: 10022326
    Abstract: Liposomal compositions comprising peptide epoxyketone compounds are described, as well as methods of making and using such liposomal compositions. These liposomal compositions enhance the therapeutic window of peptide epoxyketone compounds by improving in vivo half-life relative to non-liposomal compositions comprising peptide epoxyketone compounds, providing desirable pharmacodynamic profiles, and providing anti-tumor activity in a human tumor xenograft model, greater than or equal to non-liposomal compositions comprising peptide epoxyketone compounds. Further, experiments performed in support of the present invention demonstrated improved tolerability of liposomal compositions comprising peptide epoxyketone compounds.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: July 17, 2018
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Katherine A. Chu, Elena T. Chan, Ying Fang, Mouhannad Jamaa, Christopher Justin Kirk, Tony Muchamuel, Zhengping Wang, Jing Jiang, Jeffrey Joseph Jones
  • Patent number: 10022365
    Abstract: A liposome of irinotecan or irinotecan hydrochloride and its preparation method are disclosed. The liposome contains irinotecan or irinotecan hydrochloride, neutral phospholipid and cholesterol, wherein the weight ratio of the cholesterol to the neutral phospholipid is 1:3 to 1:5. The liposome is prepared by an ion gradient method.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: July 17, 2018
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xinyong Tong, Guofeng Lei, Chengxia Yu, Liang Chen
  • Patent number: 10017570
    Abstract: The present invention relates to an repebody capable of binding specifically to interleukin-6 (IL-6) to inhibit the biological activity of IL-6, a polynucleotide encoding the repebody, a vector comprising the polynucleotide, a recombinant microorganism having introduced therein the polynucleotide or the vector, a method of producing the repebody using the recombinant microorganism, a composition for preventing or treating cancer, which comprises the repebody, and a method for preventing or treating cancer, which comprises administering the composition for preventing or treating cancer, which comprises the repebody. The repebody of the present invention significantly reduces the activity of signal transduction and activator of transciption3 (STAT3) and the concentration of interleukin-6, and thus can be widely used as an agent for preventing or treating IL-6-related diseases.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: July 10, 2018
    Inventors: Hak-Sung Kim, Joong-Jae Lee, Jung Min Choi, Eun-Kyeong Jo, Chul-Su Yang, Hae-Kap Cheong, Hyun Jung Kim
  • Patent number: 10010848
    Abstract: This device comprises a hollow body, the hollow body defining: an internal conduit for distributing the first fluid, the internal conduit defining an inner volume; an external conduit or distributing the second fluid, the internal conduit and the external conduit extending coaxially along a longitudinal axis (AA?). It at least comprises one metal tube extending along the longitudinal axis (AA?) and being positioned in the inner volume of the internal conduit and/or in the downstream extension of the internal conduit and/or of the external conduit.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: July 3, 2018
    Assignee: CAPSUM
    Inventors: Mathieu Goutayer, Yan Eric Pafumi, Javier Angel Tesan
  • Patent number: 9999700
    Abstract: Described herein is the synthesis of adhesive from simple adhesive coacervates and their uses thereof. The adhesives are composed of (a) a polyanion in the absence of a polycation, wherein the polyanion comprises at least one crosslinking group capable of covalently crosslinking with itself, and (b) a sufficient amount of a complimentary multivalent cation or multivalent anion to produce the simple coacervate. The adhesives have numerous medical and non-medical applications.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: June 19, 2018
    Inventor: Russell J. Stewart
  • Patent number: 9993519
    Abstract: The present invention relates to an anticancer composition comprising a peptide that inhibits the proliferation of cancer stem cells present in tumor tissue and that induces apoptosis of such cancer stem cells, and more particularly, to an anticancer peptide that inhibits the activity of NF-?B which is overexpressed specifically in cancer stem cells present in tumors.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: June 12, 2018
    Inventors: Yoon Jeong Park, Chong-Pyoung Chung, Jue-Yeon Lee, Jin Sook Suh
  • Patent number: 9988420
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: June 5, 2018
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang, Yunho Jin